Skip to main content

Table 6 Comparison between pretreatment METTL3-based AML regarding of BM blasts in follow-up samples from day 28 chemotherapy till the end of the 6th month of chemotherapy

From: Methyltransferase-like 3 gene (METTL3) expression and prognostic impact in acute myeloid leukemia patients

BM blast count (%) AML cases with high normalized METTL3 gene expression (n = 25) AML cases with low normalized METTL3 gene expression (n = 15) Significance
x2 p value
Assessment of early response to chemotherapy N = 25 N = 15   
 Day 28 BM blast %
  CR 2 (8.0%) 14 (93.3%) 28.452 < 0.001**
Failure of CR 22 (88.0%) 1 (6.7%)   
Died 1 (4.0%) 0 (0.0%)   
Assessment of maintenance of CR N = 23 N = 13   
 2nd month BM blast %
  ≤ 5% 13 (56.5%) 13 (100%) 0.01*
  > 5% 8 (34.7%) 0 (0.0%)   
  Died 2 (8.7%) 0 (0.0%)   
  N = 14 N = 15   
 4th month BM blast %
  ≤ 5% 8 (57.1%) 14 (93.3%) 5.18 0.023*
  > 5% 6 (42.9%) 1 (6.7%)   
  N = 14 N = 15   
 6th month BM blast%
  ≤ 5% 6 (42.9%) 14 (93.3%) 8.62 0.003*
  > 5% 8 (57.1%) 1 (6.7%)   
  1. CR complete remission, BM bone marrow; follow-up samples from day 28 chemotherapy, χ2 Chi-square test
  2. *p value < 0.05 S; **p value < 0.001 HS